Takeda Pharmaceutical and Queen Mary University of London in England announced a major research collaboration that aims to develop new insights and therapies in gastroenterology.
Takeda's GI Drug Discovery Unit will work closely with experts from QMUL's School of Medicine and Dentistry's neurogastroenterology and immunology groups on several areas of research, including identifying novel therapeutic targets and researching the effect of compounds with novel mechanisms of action. The focus of the research alliance will be GI sensory and motor mechanisms underlying functional bowel disorders and GI motility disorders.
More articles on GI/endoscopy:
Gotham Medical Associates selects PriorityOne for GI practice IT implementation
Boston Scientific announces 2 product updates
CRE infections at UCLA Medical Center transmitted during ERCP